

## CONTENTS

	<b>Page</b>
<b>ACKNOWLEDGEMENTS</b>	i
<b>ABSTRACT</b>	ii
<b>LIST OF TABLES</b>	xiii
<b>LIST OF FIGURES</b>	xv
<b>LIST OF ABBREVIATIONS</b>	xx
<b>CHAPTER</b>	
<b>I    INTRODUCTION</b>	1
<b>II   OBJECTIVES</b>	4
<b>III  LITERRATURES REVIEW</b>	5
<b>Part I: Leptospirosis</b>	
1. History of Leptospirosis	5
2. Biology of the genus <i>Leptospira</i>	6
3. Molecular features of the genus <i>Leptospira</i>	9
4. Structures of <i>Leptospira</i> spp.	12
4.1 Periplasmic flagella or axial fibril	12
4.2 Outer membrane, outer sheath or envelope	15
4.3 Lipopolysaccharide (LPS)	19
4.4 Peptidoglycan	22
5. Classification of <i>Leptospira</i> spp.	22
6. Epidemiology	26
7. Virulent factors of <i>Leptospira</i>	27
7.1 Attachment	27
7.2 Motility	27
7.3 Toxins	28
7.4 Outer membrane proteins (OMPs)	30
8. Pathogenesis	32
9. Clinical manifestation	35
10. Diagnosis	38
10.1 General laboratory finding	38

## CONTENTS (Cont.)

	<b>Page</b>
10.2 Culture	38
10.3 Microscopic examination	41
10.4 Animal inoculation	42
10.5 Serology	42
10.6 Others serological tests	44
10.7 Molecular diagnosis	44
11. Treatment of Leptospirosis	46
12. Jarisch-herxheimer reaction	48
12.1 Mechanisms of Jarisch-herxheimer reactions	48
13. Immunity to <i>Leptospira</i> infection	49
14. Leptospirosis in Thailand	50
<b>Part II: Therapeutic antibody</b>	
1. Antibody structure and application	53
2. Evolution of antibody-based therapy	59
2.1 Serum immunotherapy	59
2.2 Specific monoclonal antibody therapy	62
2.3 Chimeric antibody	64
2.4 Humanized antibody	67
2.5 Superhumanized antibody	71
2.6 Human antibody	71
3. Humanization strategies	71
3.1 CDR-grafting	71
3.2 Crystal structure strategy	71
3.3 Best fit strategy	71
3.4 Germline based approach	71
3.5 Concensus strategy	72
3.6 Resurfacing strategy	72
3.7 Phage expressed combinatorial library	72
4. Engineered antibody fragment	72

## CONTENTS (Cont.)

	<b>Page</b>
5. Single chain variable fragment (scFv)	74
<b>IV MATERIALS AND METHODS</b>	
1. <i>Leptospira</i> cultivation	79
2. Preparation of <i>Leptospira</i> whole cells homogenate	79
3. Protein content determination	80
4. Cultivation of murine hybridoma secreting specific monoclonal antibodies (MAb) against pathogenic <i>Leptospira</i> spp.	82
5. Indirect enzyme linked-immunosorbent assay (indirect ELISA)	82
6. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)	83
6.1 Coomassie brilliant blue staining	84
6.2 Silver staining	84
7. Western blot analysis	85
8. Bioinformatics	85
9. Hemolysis dose fifty (HD50) determination and hemolysis test	86
10. Experimental animals	87
11. Lethal dose fifty (LD50) determination of <i>Leptospira interrogans</i> serogroup Pomona serovar <i>pomona</i>	87
12. <i>In vivo</i> <i>Leptospira</i> MAb LPF1 neutralization test	87
13. Hybridoma cells collection and total RNA extraction	88
14. Messenger RNA purification	89
15. First strand complementary DNA (cDNA) synthesis	89
16. Amplification of heavy and light antibody variable region genes ( <i>VH/VL</i> )	90
17. Cloning of <i>VH</i> and <i>VL</i> amplicons into pGEM <sup>®</sup> -T vector	93
18. <i>E. coli</i> transformation of recombinant pGEM <sup>®</sup> -T vector	93

## CONTENTS (Cont.)

	<b>Page</b>
19. Screening of the recombinant <i>E. coli</i> clones carrying the recombinant plasmid	94
20. Construction of recombinant murine <i>scFv</i> antibody ( <i>muscFv</i> )	94
21. Ligation of <i>Sfi</i> I- <i>Not</i> I digested <i>muscFv</i> into pCANTAB5E phagemid vector	95
22. <i>E. coli</i> transformation of murine <i>scFv</i> recombinant phagemid	96
23. Rescue of phages carrying muscFv antibody	96
24. Preparation of phages expressing muscFv antibody	97
25. Immobilization of <i>Leptospira</i> antigen onto solid surface	97
26. Biopanning	97
27. Phage ELISA	98
28. Amplification of <i>muscFv</i> gene from selected phage clones	99
29. <i>Mva</i> I restriction endonuclease analysis	99
30. Expression of recombinant scFv antibody	100
31. Extraction of periplasmic contents of the recombinant <i>E. coli</i>	100
32. Purification of recombinant scFv antibody by anion-exchange chromatography column	101
33. Purification of recombinant scFv antibody by anti-E-tag affinity chromatography	101
34. Purification of recombinant scFv antibody by <i>Leptospira</i> coupled CNBr-activated Sepharose-4B affinity chromatography	102
34.1 Coupling of leptospire antigen to CNBr-activated sepharose-4B	102
34.2 Purification of <i>Leptospira</i> specific scFv	102

## CONTENTS (Cont.)

	<b>Page</b>
35. Identification of murine immunoglobulin frameworks (FRs) and complementarity determining regions (CDRs)	103
36. Selection and amplification of most matched-human VH and VL sequences to the murine VH and VL sequences	103
37. Construction of humanized-murine <i>scFv</i> ( <i>huscFv</i> ) against pathogenic <i>Leptospira</i>	104
38. Preparation of human immunoglobulins	107
39. Purification of human immunoglobulin by protein A-sepharose CL-4B	107
40. Preparation of polyclonal rabbit anti-human light chain antibody	107
41. Characterization of antigenic specificity of recombinant <i>muscFv</i> and <i>huscFv</i>	108
42. <i>In vivo</i> <i>Leptospira</i> neutralization test by recombinant <i>huscFv</i>	109
43. <i>Leptospira</i> culture from clinical samples	110
44. Hematoxylin and eosin (H&E) staining of tissue sections	110
 <b>V RESULTS</b>	
1. Characterization of murine monoclonal antibody clone LPF1	112
1.1 Monoclonal antibody clone LPF1 inhibits red blood cell (RBC) hemolysis mediated from pathogenic <i>Leptospira in vitro</i>	115
1.2 Monoclonal antibody clone LPF1 neutralizes heterologous pathogenic <i>Leptospira</i> infection in hamster model	120
1.3 Monoclonal antibody clone LPF1 decreased pathological lesions in hamster infected with heterologous pathogenic <i>Leptospira</i>	131

## CONTENTS (Cont.)

	<b>Page</b>
1.3.1 Lung	131
1.3.2 Heart	131
1.3.3 Liver	131
1.3.4 Spleen	132
1.3.5 Kidney	132
2. Construction of murine <i>scFv</i> ( <i>muscFv</i> ) from hybridoma clone LPF1	147
3. Selection of <i>E. coli</i> TG1 carrying <i>muscFv</i> recombinant vectors	154
4. Determination of murine frameworks and CDRs of VH and VL and selection of the most matched-human VH and VL sequences to the murine VH and VL sequences	162
5. Production of humanized-murine <i>scFv</i> ( <i>huscFv</i> ) DNA sequence	169
6. Selection of <i>E. coli</i> TG1 carrying <i>huscFv</i> recombinant phagemids	176
7. Recombinant protein expression of murine ( <i>muscFv</i> ) and humanized-murine <i>scFv</i> ( <i>huScFv</i> )	180
8. Purification of murine ( <i>muScFv</i> ) and humanized-murine <i>scFv</i> ( <i>huscFv</i> ) recombinant protein	182
9. Verification of humanized-murine <i>scFv</i> ( <i>huscFv</i> ) recombinant protein	186
10. Production of rabbit anti-human light chain polyclonal antibody	186
11. Determination of antigenic specificity of MAb LPF1 and <i>scFv</i> derivatives	187
12. Three dimensional structure prediction of <i>muscFv</i> and <i>huscFv</i>	192

**CONTENTS (Cont.)**

	<b>Page</b>
13. muscFv and huscFv neutralize heterologous <i>Leptospira</i> mediated-hemolysis <i>in vitro</i>	196
14. HuscFv neutralized heterologous <i>Leptospira</i> infection <i>in vivo</i>	198
<b>VI DISCUSSION</b>	212
<b>VII CONCLUSION</b>	219
<b>REFERENCES</b>	220
<b>APPENDIX A</b>	248
<b>APPENDIX B</b>	251
<b>APPENDIX C</b>	253
<b>APPENDIX D</b>	256
<b>APPENDIX E</b>	262
<b>APPENDIX F</b>	265
<b>APPENDIX G</b>	268
<b>APPENDIX H</b>	270
<b>APPENDIX I</b>	276
<b>APPENDIX J</b>	279
<b>APPENDIX K</b>	281
<b>APPENDIX L</b>	284
<b>BIOGRAPHY</b>	287